Abstract:Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several compounds, such as 6, 14, 15, 21, 30, and 33, were found to be potent inhibitors against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels. Detailed structure–activity relationships were obtained by utilizing the variation of moieties within the corresponding pharmacophores. In vitro metabolic stability profiles and some drug-like properties of selected compounds were assessed, furnishing the preliminary structure–metabolic stability relationships. Furthermore, molecular modeling studies elucidated the binding modes of compounds 6, 15, 21, and 30 in the binding pocket of WT, E138K, K103N, or Y181C HIV-1 RTs. These promising compounds can be used as lead compounds and warrant further structural optimization to yield more active HIV-1 inhibitors.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00987.Molecular formula strings (CSV)In vitro anti-HIV assays in MT-4 cells; WT HIV-1 RT inhibition assays; metabolic stability assays in human liver microsomes; molecular modeling; predicted miLogP and MolLogP values of target compounds and controls; mean distance and standard deviation values for selected ligand–protein contacts in simulated systems; regression analysis of miLogP values and MolLogP values; rmsd profiles for the protein backbone, NNRTI-binding site, and simulated inhibitors for the RT-inhibitor complexes; time-dependent distance distribution for d1–d4 for RT-inhibitor complexes; representation of the molecular interaction potential for the interaction of compounds 6, 15, 21, and 30 with a positively and a negatively charged atom; and 1H NMR, 13C NMR, and ESI-MS spectra for the target compounds (PDF).This article has not yet been cited by other publications.

An enzymatic route to the synthesis of tricyclic fused hexahydrofuranofuran P2-Ligand for a series of highly potent HIV-1 protease inhibitors

Advances in the synthesis of (3R,3aS,6aR)-hexahydrofuro-[2,3-b]furan-3-ol, a key ligand of the HIV protease inhibitors

Synthesis of the C5–C30 fragment of cyclodidemniserinol trisulfate via I2-mediated deprotection and ring closure tandem reaction

Design and Synthesis of Potent HIV-1 Protease Inhibitors with (S)-Tetrahydrofuran-tertiary Amine-Acetamide As P2−ligand: Structure−activity Studies and Biological Evaluation

Synthesis of a Long Acting HIV Protease Inhibitor Via Metal or Enzymatic Reduction of the Appropriate Chloro Ketone and Selective Zinc Enolate Condensation with an Amino Epoxide

Synthetic studies of the HIV-1 protease inhibitive didemnaketals: stereocontrolled synthetic approach to the key mother spiroketals.

A New Synthesis of Enantiopure Amine Fragment: An Important Intermediate to the Anti-HIV Drug Lenacapavir

Efficient Synthesis of the C1-C7 Fragment of Didemnaketal A

Stereoselective Access to Furan-fused [5.5.0] Bicyclic Heterocycles Enabled by Gold-Catalyzed Asymmetric [8+4] Cycloaddition

Synthesis of 1-Hydroxy-10-methyl-pyrimido [1, 6-C][1, 3]oxazine and the Oxazepine Derivative, Structural Mimicry of Anti-Constrained Acyclic Thymidine

Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes As C2-Symmetric HIV-1 Protease Inhibitors and Docking Study.

Total Synthesis of Anti-Hiv Agent Chloropeptin I.

Synthesis and Evaluation of Anti-HIV-1 Activities of Novel 7-Hydroxy-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-4-carboxylate Derivatives

Design, Synthesis, and Structure−Activity Relationship of a Novel Series of 2-Aryl 5-(4-Oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 Entry Inhibitors<sup>⊥</sup>

Selective 1,4-Syn-addition to Cyclic 1,3-Dienes Via Hybrid Palladium Catalysis

Catalytic Asymmetric Desymmetrization of Cyclopentendiones Via Diels-Alder Reaction of 3-Hydroxy-2-pyrones: Construction of Multifunctional Bridged Tricyclic Lactones.

Pharmacophore-fusing Design of Pyrimidine Sulfonylacetanilides As Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase.

Complementary Asymmetric Routes to Fused Tricyclic (R)-2,3,4,4A,5,6-hexahydro-1h-pyrazino[1,2-a]quinolines and (R)-1,2,3,4,5,5A,6,7-octahydro-[1,4]diazepino[1,2-a]quinolines

Design, Synthesis, and Biological Evaluation of Novel HIV-1 Protease Inhibitors Containing Pyrrolidine-Derived P2 Ligands to Combat Drug-Resistant Variant

A new route into hexahydro-cyclopenta[b]pyrrole-cis-3a,6-diols. Synthesis of constrained bicyclic analogues of pyrrolidine azasugars

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies